Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma

血液学 医学 多发性骨髓瘤 内科学 家庭医学
作者
Surbhi Sidana,Dragan Jevremović,Rhett P. Ketterling,Nidhi Tandon,Patricia Theresa Greipp,Linda Banovic Baughn,Angela A. Dispenzieri,Morie Abraham Gertz,S. Vincent Rajkumar,Shaji Kunnathu Kumar
出处
期刊:American Journal of Hematology [Wiley]
卷期号:94 (5): E117-E120 被引量:24
标识
DOI:10.1002/ajh.25420
摘要

Cytogenetic assessment of plasma cells (PCs) provides prognostic information for patients with multiple myeloma (MM) and is most commonly carried out using fluorescence in situ hybridization (FISH) testing or conventional karyotype analysis, although the latter is currently less commonly used.1-3 Hyperdiploidy, with trisomies of odd numbered chromosomes typically portends a favorable prognosis, while hypodiploidy, certain translocations of immunoglobulin heavy chain (IgH) locus [t(4;14), t(14;16), and t(14;20)], deletion of 17p/monosomy 17 and gain of 1q are adverse prognostic factors.1-11 Tetraploidy, which refers to a doubling of the diploid genome, is less commonly observed in MM.5, 12, 13 There is limited data on the frequency of this finding and its prognostic impact in MM.14 In this report, we describe the incidence of tetraploidy in patients with newly diagnosed MM using a flow cytometry based method described below. We also report on genetic abnormalities that are associated with tetraploidy, as well as survival outcomes in this group compared to patients without tetraploidy. We evaluated 275 consecutive patients with symptomatic MM diagnosed from April 2, 2012 to December 3, 2015 who underwent Plasma Cell Proliferative Index (PCPRO) testing before start of first-line therapy and they comprise the study population. We have developed a method of assessing ploidy of plasma cells, the PCPRO, which is a flow cytometry based method that can estimate the DNA index of PCs.17 This is done by calculating the ratio of DNA content of clonal PCs to polytypic PCs, which serve as a control in each patient. PCPRO can also measure percentage of plasma cells in S-phase of cell cycle,15 thereby providing an estimate of proliferative rate. The detailed procedural method to determine DNA index and S-phase using PCPRO is described in the Supporting Information. DNA index values of 0.95-1.05 were considered diploid. Values below 0.95 were considered hypodiploid and values between 1.06 and 1.50 were considered hyperdiploid. Values from between 1.51 and 1.7 were considered near-tetraploid and values >1.7 with >10% clonal G2M cells and a visible 4n population were considered tetraploid. Conventional karyotype analysis and plasma cell FISH results are also reported. FISH testing was carried out by interphase cytoplasmic immunoglobulin FISH (cIg-FISH) for plasma cell disorders as previously described.8, 16 Statistical analysis was carried out using the JMP (version 13, SAS Institute Inc., Cary, NC). Overall survival (OS) and progression free survival were estimated by the Kaplan Meier method and log-rank test was used to compare survival curves to evaluate prognostic impact of tetraploidy on survival. Chi-Square and Fischer Exact tests were used to carry out univariate analysis for categorical variables and Wilcoxon Rank Sum/Kruskal Wallis for continuous variables. Of the 275 patients with newly diagnosed MM (NDMM), tetraploidy by PCPRO was observed in 17 (6%) patients and the remaining 258 (94%) patients were non-tetraploid (hyperdiploid: n = 147, 53%; diploid: n = 98, 36%; hypodiploid: n = 10, 4%, near-tetraploid: n = 3, 1%). In the tetraploid group, a tetraploid clone or sub-clone was observed in 71% (12/17) patients by concurrent FISH testing. Conventional karyotyping revealed a normal karyotype in 71% (12/17) patients and complex karyotype in 24% (4/17) of patients and deletion 20q in the remaining one patient (Supporting Information Table S1). Table 1 describes the baseline characteristics, as well as treatment and response to therapy in patients with tetraploidy versus non-tetraploidy by PCPRO. There was no difference in the age at diagnosis and the proportion of males versus females between the 2 groups. There was no statistically significant difference in the ISS stage distribution in the 2 groups, although fewer patients with tetraploidy were observed to have ISS stage 1 disease (13% vs. 30%). Patients in the tetraploidy group were observed to have higher median bone marrow plasma cells compared with the non-tetraploidy group (70% vs. 40%, P = .002). They were also more likely to have high-risk genetic abnormalities [defined as deletion 17p/monosomy 17, t(4;14), t(14;16), and t(14;20)] on concurrent FISH testing (59% vs. 19%, P < .001). In particular, patients with tetraploidy had a significantly higher incidence of deletion 17p/monosomy 17 (29% vs. 11%, P = .048) and t(14;16) (24% vs. 2%, P < .001). Patients with tetraploidy also had higher rates of t(11;14) (47% vs. 22%, P = .03) and 1q gain (24% vs. 8%, P = .05) compared with non-tetraploid patients. Monosomy 13 was also more common in the tetraploid group (71% vs. 35%, P = .003), though no significant difference was observed for presence of 13q deletion (6% in both, P > .99). On the other hand, tetraploid patients were less likely to harbor trisomies of odd numbered chromosomes (12% vs. 64%, P < .001). The median percentage of plasma cells in S-phase was numerically higher in the tetraploidy group, indicating a slightly higher proliferative rate, but it did not meet statistical significance (1.2% vs. 0.9%, P = .06). All treated patients received novel agent based treatment with a proteasome inhibitor based regimen being used in 82% versus 71% (P = .3) patients in the tetraploidy versus non-tetraploidy groups. Similar rates of upfront transplant were observed across the two groups (35% vs. 40%, P = .7). No difference was observed in the rates of best hematologic response to first-line therapy, with rates of very good partial response or better in the tetraploid versus non-tetraploid group being 75% versus 68%, respectively (P = .6). Median follow-up for all patients was 49 months from start of first-line therapy. The median OS in patients with tetraploidy at diagnosis versus those without tetraploidy was 29 months versus not reached, P < .001 (Figure 1A). One and 2-year estimated OS in the tetraploidy group was 82% and 53% compared with 91% and 80% in the non-tetraploidy group, respectively. As patients with tetraploidy were more likely to have high-risk FISH abnormalities, a sub-group analysis was conducted for patients with high-risk FISH abnormalities. Even in the subset of patients who had high-risk FISH [defined as deletion 17p, t(4;14), t(14;16), and t(14;20)], patients with tetraploidy (n = 10) had inferior OS compared to those without tetraploidy (n = 49), with median OS of 25 versus 54 months, P = .04, respectively (Figure 1B). In the standard risk group, patients with tetraploidy had numerically lower OS (40 months vs. not reached), but it did not quite reach statistical significance (P = .09). In conclusion, tetraploidy resulting from a doubling of the diploid genome (4n) is observed in a small proportion of patients with MM, with 6% patients in our study demonstrating tetraploidy using a flow cytometry based method to assess ploidy. Patients with tetraploidy were more likely to have associated high-risk genetic abnormalities. Interestingly, simultaneous tetraploidy was noted in 12/17 patients on FISH testing. This discrepancy may be due to assessment of a limited number of cells for FISH evaluation compared to flow cytometry. Tetraploidy is often a subclonal finding on flow cytometry. Moreover, at our institution, FISH reporting requires that an abnormality be present in at unless 10% of cells. At present, there is limited information on prognostic implications of tetraploidy in myeloma by FISH testing or other techniques. We observed that tetraploidy is associated with a poor prognosis in patients with NDMM, even in the sub-group with high-risk FISH abnormalities. This finding is of significant interest as it may identify a sub-group of NDMM patients with poor prognosis, who may be candidates for more aggressive risk adapted therapy in future. However, as our sample size is small, this finding requires further validation in a larger cohort of patients. SS: Honoraria/consultancy: Janssen; AD: Consultant for Takeda; Research funding from Celgene, Takeda, Janssen; GlaxoSmithKline, Alnylam, and Pfizer; MAG: Honoraria/consultancy from Ionis, Alnylam, Prothena, Celgene, Janssen, Specytrum, Annexon, Apellis, Amgen, Medscape, Abbvie, Research to Practice, Physcians Education Resource and Teva; SKK: Research Funding and membership on an entity's Board of Directors or advisory committees: AbbVie, Celgene, Janssen KITE, Merck. Membership on an entity's Board of Directors or advisory committees: Oncopeptides, Takeda. Research funding from Novartis and Roche; Remaining authors: None. SS and SKK designed the study, collected, analyzed and interpreted data, performed statistical analyses, wrote the manuscript. DJ analyzed and interpreted data and wrote the manuscript. NT collected data and critically appraised the manuscript. All remaining authors critically appraised and edited the manuscript. Appendix S1: Supporting Information Table S1: Conventional metaphase karyotype results on patients with tetraploidy on PCPRO testing Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
捏鱼发布了新的文献求助10
刚刚
顺利的盼曼完成签到,获得积分10
2秒前
。。完成签到,获得积分10
2秒前
无私青柏发布了新的文献求助10
2秒前
0_1完成签到,获得积分10
2秒前
2秒前
1234567发布了新的文献求助10
3秒前
你的微笑我舍不得完成签到,获得积分10
3秒前
4秒前
cheems完成签到,获得积分10
4秒前
Ulrica发布了新的文献求助20
6秒前
刘星星完成签到,获得积分10
7秒前
大林子发布了新的文献求助10
8秒前
weiwei完成签到,获得积分10
8秒前
科研通AI6.3的应助被苹果亦巧采纳,获得10
8秒前
9秒前
9秒前
zx关闭了zx的文献求助
10秒前
夏目如许发布了新的文献求助10
10秒前
结球完成签到,获得积分20
10秒前
10秒前
秀丽的剑心完成签到,获得积分10
11秒前
YUMI完成签到,获得积分10
12秒前
bgt发布了新的文献求助150
12秒前
粗暴的冬瓜完成签到,获得积分10
13秒前
13秒前
13秒前
一页墨城发布了新的文献求助10
14秒前
无花果的应助被君子之昔采纳,获得10
14秒前
14秒前
今后的应助被12采纳,获得10
14秒前
酷酷元风完成签到,获得积分10
14秒前
zyy发布了新的文献求助10
14秒前
15秒前
lulu完成签到 ,获得积分10
15秒前
jingyao完成签到 ,获得积分10
15秒前
智智完成签到 ,获得积分10
16秒前
酷波er的应助被毛毛采纳,获得10
16秒前
17秒前
又活了一天完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175142
求助须知:如何正确求助?哪些是违规求助? 9566928
关于积分的说明 21789123
捐赠科研通 7769522
什么是DOI,文献DOI怎么找? 3431822
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477222